

---

## WilmerHale Represents Aileron Therapeutics in IPO

JULY 6, 2017

On June 28, 2017, Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of \$15.00 per share, before underwriting discounts and commissions. All of the shares were offered by Aileron. In addition, Aileron granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock from the company at the public offering price. Aileron's common stock began trading on the NASDAQ Global Market under the ticker symbol "ALRN" on Thursday, June 29, 2017.

The WilmerHale team representing Aileron in its IPO was led by [Stuart Falber](#) and included [Josh Fox](#), [Craig Hilts](#), [Tim Kulis](#), [Mike Lopes](#) and [Jenna Ventrino](#).

[View Aileron's press release.](#)